ARTICLE | Company News
GlaxoSmithKline, Institute of Cancer at Barts, Queen Mary, University of London proteomics, inflammation news
April 26, 2010 7:00 AM UTC
The institute and the university spun out their cell signaling pathway technology into newco Activiomics Ltd. Activiomics will use its Targeted In-depth Quantification of Cell Signalling (TIQUAS) mass spectrometry platform to quantify phosphopeptides for biomarker discovery and drug profiling for biotech and pharmaceutical companies. ...